- Royalty Pharma (RPRX, Financial) announces a quarterly dividend of $0.22 per Class A ordinary share for Q2 2025.
- The dividend is payable on June 10, 2025, to shareholders of record by May 16, 2025.
- Royalty Pharma continues to provide consistent returns to its shareholders.
Royalty Pharma (RPRX), a leader in the biopharmaceutical industry, has declared a quarterly dividend of $0.22 per Class A ordinary share for the second quarter of 2025. This decision was approved by the company's board of directors, highlighting the company's commitment to delivering consistent shareholder returns.
The scheduled date for the dividend distribution is June 10, 2025. Shareholders must be on record by the close of business on May 16, 2025, to be eligible for this payout, ensuring that the company's stakeholders benefit from their investments.
Founded in 1996, Royalty Pharma is the largest acquirer of biopharmaceutical royalties and plays a pivotal role in funding innovation within the industry. The company's diverse portfolio includes royalties from over 35 commercial products, ranging from Vertex's Trikafta to Gilead's Trodelvy, reinforcing its influence in the biopharmaceutical landscape.
For further information on Royalty Pharma and its financial activities, investors are encouraged to visit the company's website or contact Investor Relations.
Also check out: (Free Trial)
